Keros Therapeutics Files 8-K

TL;DR

Keros Therapeutics filed a standard 8-K on Sept 3rd. No major news yet.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on September 3, 2024, to report other events and financial statements. The filing does not contain specific details about material events or financial performance within the provided text, but indicates a standard regulatory update.

Why It Matters

This filing serves as a regulatory notification for Keros Therapeutics, Inc., informing stakeholders of significant events or financial updates as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — Registrant
• September 3, 2024 (date) — Date of earliest event reported
• 001-39264 (company) — SEC File Number
• 81-1173868 (company) — I.R.S. Employer Identification No.
• 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421 (location) — Principal executive offices address
• 617-314-6297 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

• kros-20240903.htm (8-K) — 37KB
• exhibit9919324pr.htm (EX-99.1) — 10KB
• 0001664710-24-000075.txt ( ) — 176KB
• kros-20240903.xsd (EX-101.SCH) — 2KB
• kros-20240903_lab.xml (EX-101.LAB) — 22KB
• kros-20240903_pre.xml (EX-101.PRE) — 13KB
• kros-20240903_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 3, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension. As a result, the Company expects to complete enrollment of that trial by the end of September 2024 and present topline data in the second quarter of 2025. Attached hereto as Exhibit 99.1 and incorporated herein by reference is a copy of the press release. This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expected timing for enrollment completion and data readout for the TROPOS trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize, including those risk factors discussed or referred to in the Company's filings with the SEC, including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated September 3 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: September 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR